Active substance
Pimecrolimus
- SFDA 4
- US FDA 3
- Health Canada 1
- US price lines 3
- NHS prices 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ELIDEL 1% CREAM | 1 % | Cream · Topical | 1 Tube | SAR 112.35 | NCE · Prescription | Viatris Healthcare GmbH | Valid |
| ELIDEL 1% CREAM | 1 % | Cream · Topical | 1 Tube | SAR 63.50 | NCE · Prescription | MEDA PHARMA GmbH & Co KG | Withdrawn by MAH · Not Marketed |
| ELIDEL 1% CREAM | 1 % | Cream · Topical | 1 Tube | SAR 83.80 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
| ELIDEL 1% CREAM | 1 % | Cream · Topical | 1 Tube | SAR 147.50 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ECZEMA; LICHEN PLANUS; PSORIASIS; SEBORRHEIC DERMATITIS; VITILIGO
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ELIDEL | 1% | cream · topical | BAUSCH | Prescription | 13 Dec 2001 |
| PIMECROLIMUS | 1% | cream · topical | ACTAVIS LABS UT INC | Prescription | 27 Dec 2018 |
| PIMECROLIMUS | 1% | cream · topical | GLENMARK PHARMS LTD | Prescription | 29 Aug 2019 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ELIDEL | 02247238 | 1 % / W/W | CREAM · TOPICAL | BAUSCH HEALTH, CANADA INC. |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | PIMECROLIMUS 1% CREAM | $3.31494 | per GM | 23 Sep 2026 |
| US NADAC | PIMECROLIMUS 1% CREAM | $3.10475 | per GM | 23 Sep 2026 |
| US NADAC | PIMECROLIMUS 1% CREAM | $3.3861 | per GM | 23 Sep 2026 |
| NHS Drug Tariff | Pimecrolimus 1% cream | £19.69 | 30 gram | 1 Oct 2026 |
| NHS Drug Tariff | Pimecrolimus 1% cream | £37.41 | 60 gram | 1 Oct 2026 |
| NHS Drug Tariff | Pimecrolimus 1% cream | £59.07 | 100 gram | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.